Pfizer Pre-Tax Profit Margin 2010-2023 | PFE
Current and historical pre-tax profit margin for Pfizer (PFE) from 2010 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Pfizer pre-tax profit margin for the three months ending December 31, 2023 was .
| Pfizer Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2023-12-31 |
$58.50B |
$1.06B |
1.81% |
| 2023-09-30 |
$68.54B |
$10.42B |
15.20% |
| 2023-06-30 |
$77.94B |
$22.77B |
29.21% |
| 2023-03-31 |
$92.95B |
$31.95B |
34.37% |
| 2022-12-31 |
$100.33B |
$34.73B |
34.61% |
| 2022-09-30 |
$99.88B |
$33.33B |
33.37% |
| 2022-06-30 |
$101.28B |
$32.17B |
31.76% |
| 2022-03-31 |
$92.43B |
$27.67B |
29.93% |
| 2021-12-31 |
$81.29B |
$24.31B |
29.91% |
| 2021-09-30 |
$68.88B |
$21.08B |
30.61% |
| 2021-06-30 |
$55.12B |
$13.81B |
25.05% |
| 2021-03-31 |
$46.08B |
$9.89B |
21.45% |
| 2020-12-31 |
$41.65B |
$7.04B |
16.89% |
| 2020-09-30 |
$32.07B |
$-1.43B |
-4.47% |
| 2020-06-30 |
$34.47B |
$8.73B |
25.31% |
| 2020-03-31 |
$37.87B |
$9.84B |
25.98% |
| 2019-12-31 |
$40.91B |
$11.32B |
27.68% |
| 2019-09-30 |
$40.22B |
$9.95B |
24.75% |
| 2019-06-30 |
$40.84B |
$3.40B |
8.34% |
| 2019-03-31 |
$41.04B |
$3.79B |
9.24% |
| 2018-12-31 |
$40.83B |
$3.59B |
8.80% |
| 2018-09-30 |
$53.37B |
$13.79B |
25.83% |
| 2018-06-30 |
$53.24B |
$13.19B |
24.78% |
| 2018-03-31 |
$52.67B |
$12.48B |
23.70% |
| 2017-12-31 |
$52.55B |
$12.31B |
23.42% |
| 2017-09-30 |
$52.47B |
$12.13B |
23.11% |
| 2017-06-30 |
$52.35B |
$10.15B |
19.38% |
| 2017-03-31 |
$52.60B |
$8.74B |
16.62% |
| 2016-12-31 |
$52.82B |
$8.35B |
15.81% |
| 2016-09-30 |
$53.24B |
$7.22B |
13.56% |
| 2016-06-30 |
$52.29B |
$8.32B |
15.90% |
| 2016-03-31 |
$50.99B |
$9.44B |
18.52% |
| 2015-12-31 |
$48.85B |
$8.97B |
18.35% |
| 2015-09-30 |
$47.92B |
$11.12B |
23.21% |
| 2015-06-30 |
$48.20B |
$12.01B |
24.92% |
| 2015-03-31 |
$49.12B |
$12.48B |
25.40% |
| 2014-12-31 |
$49.61B |
$12.24B |
24.67% |
| 2014-09-30 |
$50.05B |
$13.50B |
26.97% |
| 2014-06-30 |
$50.33B |
$13.48B |
26.79% |
| 2014-03-31 |
$50.53B |
$14.84B |
29.37% |
| 2013-12-31 |
$51.58B |
$15.72B |
30.47% |
| 2013-09-30 |
$50.88B |
$14.48B |
28.45% |
| 2013-06-30 |
$51.19B |
$13.71B |
26.78% |
| 2013-03-31 |
$52.18B |
$12.53B |
24.02% |
| 2012-12-31 |
$54.66B |
$11.24B |
20.57% |
| 2012-09-30 |
$53.25B |
$10.65B |
19.99% |
| 2012-06-30 |
$56.90B |
$11.38B |
20.00% |
| 2012-03-31 |
$59.42B |
$10.80B |
18.17% |
| 2011-12-31 |
$61.04B |
$11.48B |
18.81% |
| 2011-09-30 |
$65.06B |
$11.24B |
17.28% |
| 2011-06-30 |
$64.44B |
$9.11B |
14.14% |
| 2011-03-31 |
$65.09B |
$9.44B |
14.50% |
| 2010-12-31 |
$65.17B |
$9.47B |
14.53% |
| 2010-09-30 |
$65.50B |
$8.34B |
12.73% |
| 2010-06-30 |
$61.13B |
$10.90B |
17.83% |
| 2010-03-31 |
$54.98B |
$10.02B |
18.23% |
| 2009-12-31 |
$49.27B |
$10.67B |
21.66% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$147.226B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
